Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2006113828 - UTILISATION DE MATRICES IN SITU BIOCOMPATIBLES POUR L'ADMINISTRATION DE CELLULES THERAPEUTIQUES AU COEUR

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

WHAT IS CLAIMED:
1. A method for delivering therapeutic cells to the heart of a subject, comprising: a) forming one or more channels within a region of a wall of the subject's heart which includes a myocardial layer; and b) delivering to said region a composition comprising living cells and a biocompatible matrix that forms in situ upon exposure to a physiological condition, wherein said living cells provide a therapeutic effect.
2. The method of claim 1, wherein the cells provide the therapeutic effect naturally.
3. The method of claim 1, wherein the cells are recombinantly engineered to provide the therapeutic effect.

4. The method of claim 1, wherein the therapeutic cells secrete a growth factor.
5. The method of claim 4, wherein the growth factor is selected from the group consisting of vascular endothelial growth factor (VEGF) , platelet derived growth factor (PDGF-BB, PDGF-CC or PDGF-DD), angiopoietin-1 (Ang-1) , acidic fibroblast growth factor (aFGF) , basic fibroblast growth factor (bFGF) , and transforming growth factor-βl (TGF-βl) .
6. The method of claim 1, wherein the therapeutic cells are contractile cells.
7. The method of claim 6, wherein the therapeutic cells are selected from the group consisting of hematopoietic stem cells (including bone marrow, circulating and umbilical cells), mesenchymal stem cells, myoblasts (including skeletal and cardiac myoblasts), satellite cells, embryonic stem cells or progenitor cells (including endothelial progenitor cells and cardiac progenitor cells) , cardiomyocytes, fibroblasts and skeletal myocytes.

8. The method of claim 7, wherein the therapeutic cells are obtained from allogeneic, xenogeneic, transgeneic, or autogeneic sources.
9. The method of claim 1, wherein the physiological condition is selected from the group consisting of temperature, pH, water content and ion concentration.
10. The method of claim 9, wherein the biocompatible matrix is selected from the group consisting of a thermoplastic paste, an in situ crosslinked system, such as a thermoset or an ion-mediated gelating system; an in situ precipitating system with a sol-gel transition induced by solvent removal, temperature or pH; and an organogel.
11. The method of claim 10, wherein the biocompatible matrix comprises components selected from the group consisting of D,L-lactide, glycolide, ε-caprolactone, trimethylene carbonate, dioxanone, ortho esters, poly (ethylene glycol), alginate, sucrose acetate isobutyrate, poly (lactide-co-glycolide) , poly (acrylic acid), poly (N-isopropylacrylamide) (PNIPAAM), methylcellulose (MC), MC-grafted PNIPAAM, poly (ethylene glycol) -poly (lactic acid) -poly (ethyleneglycol) triblocks (PEG-PLA-PEG), PEG-PLA diblock copolymers, poly (ethylene oxide) -poly (propylene oxide) -poly (ethylene oxide) (PEO-PPO-PEO) triblocks (Pluronics® or Poloxamer®) , capped PEO-PPO-PEO, PEO-poly(L-lactic acid-co-glycolic acid) (PEO-PLLGA), PEO-poly(DL-lactic acid-co-glycolic acid (PEO-PLGA) block and graft copolymers, PEG-PLGA-PEG, PLGA-PEG-PLGA, poly (organophosphazene) s, chitosan-based and silk-elastin polymers, hydroxypropyl-cellulose (Carbopol®) , chitosan, peanut oil and waxes .
12. The components of claim 11, wherein the components are modified to facilitate cell adhesion and cell growth.

13. The modifications of claim 12, wherein the modification includes the introduction of RGD-sites.
14. The method of claim 1, wherein the composition further comprises one or more therapeutic agents .
15. The method of claim 14, wherein the therapeutic agent or agents is selected from the group consisting of vascular endothelial growth factor (VEGF) , platelet derived growth factor (PDGF-BB, PDGF-CC or PDGF-DD) , angiopoietin-1 (Ang-1), acidic fibroblast growth factor (aFGF) , basic fibroblast growth factor (bFGF) , and transforming growth factor-βl (TGF-βl) , estrogen, heparin sulphates and oligomeric regenerating agents (RGTAs).
16. The method of claim 1, wherein the subject is a patient suffering from heart disease.
17. A system for delivering therapeutic cells to the heart of a subject, comprising: a) means for forming one or more channels within a region of a wall of the subject's heart which includes a myocardial layer; (b) means for introducing into said region a composition comprising living cells and a biocompatible matrix that forms in situ upon exposure to a physiological condition, wherein said living cells provide a therapeutic effect.
18. The system of claim 17, wherein the channel forming means is selected from the group consisting of laser transmyocardial revascularization, high frequency current transmyocardial revascularization, percutaneous laser myocardial revascularization, high frequency current myocardial revascularization, mechanical transmyocardial revascularization and mechanical percutaneous myocardial revascularization.
19. The system of claim 18, wherein the channel forming means comprises a catheter.

20. The system of claim 18, wherein the channel forming means comprises a hollow needle.
21. The system of claim 17, wherein the composition introducing means comprises a catheter.
22. The system of claim 21, wherein the composition introducing means further comprises a delivery element selected from the group consisting of a hollow needle, a coated delivery surface, a perfusion port and a delivery-lumen .
23. The system of claim 17, wherein the subject is a patient suffering from heart disease.